Fenofibrate tablets, which can be taken regardless of meals, will be listed for the first time in Korea. Fenofibrate is a drug used for primary hyperlipidemia. Existing drugs should be administered after meals. Therefore, the newly registered product is expected to improve the convenience of patients.

According to the MOHW on the 24th, Yuhan's Fenowell 145mg will be listed at 339 won on the 1st of next month. Fenowell 145 mg is the only Fenofibrate tablet with 145 mg. In addition, it has the advantage of oral administration regardless of meals.

It is used for primary hyperlipidemia such as hypercholesterolemia (Type IIa), hypercholesterolemia and hypertriglycerideemia (Type IIb, Type III)